The Expression of MicroRNA-155 in Plasma and Tissue Is Matched in Human Laryngeal Squamous Cell Carcinoma.
10.3349/ymj.2016.57.2.298
- Author:
Jian Ling WANG
1
;
Xin WANG
;
Dong YANG
;
Wen Jie SHI
Author Information
1. Department of Otolaryngol Head Neck Surgery, General Hospital of Tianjin Medical University, Tianjin, China.
- Publication Type:Original Article
- Keywords:
MiR-155;
laryngeal squamous cell carcinoma;
diagnosis;
biomarker
- MeSH:
Aged;
Biomarkers, Tumor/blood/*genetics;
Carcinoma, Squamous Cell/blood/diagnosis/*genetics;
Case-Control Studies;
Early Diagnosis;
Female;
Gene Expression Profiling;
Gene Expression Regulation, Neoplastic;
Head and Neck Neoplasms;
Humans;
Laryngeal Neoplasms/blood/diagnosis/*genetics;
Male;
MicroRNAs/*blood;
Middle Aged;
Prognosis;
Real-Time Polymerase Chain Reaction;
Up-Regulation
- From:Yonsei Medical Journal
2016;57(2):298-305
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Tumor-associated microRNAs have been detected in cancer, though whether plasma microRNA-155 (miR-155) could be a potential biomarker for laryngeal squamous cell carcinoma (LSCC) prognosis is unclear. We aimed to determine how miR-155 can be used to predict the clinical characteristics of patients with LSCC and correctly diagnose them. MATERIALS AND METHODS: We collected tissue samples and peripheral blood samples before and after treatment from 280 LSCC cases and 560 controls. Real-time quantitative reverse transcription PCR was employed in this study to compare the relative expression of miR-155. RESULTS: A total of 280 LSCC patients and 560 age- and sex-matched controls were included in the study. The miR-155 level was more up-regulated in LSCC tissue than in the non-tumor tissues (13.6+/-2.4 vs. 3.1+/-0.80, p<0.001). Additionally, a significantly higher miR-155 level in plasma samples from LSCC patients than in those of the controls (8.9+/-1.25 vs. 1.8+/-0.8, p<0.001) was reported. Tissue miR-155 showed an area under the curve (AUC) of 0.933, with a sensitivity of 82.6% and a specificity of 89.2%. The AUC for plasma miR-155 was 0.757, with a sensitivity of 58.4% and a specificity of 69.5%. When early LSCC in TNM I stage was considered, tissue miR-155 showed an area under the curve of 0.804, with a sensitivity of 85.2% and a specificity of 87.3%. CONCLUSION: The expression of tissue and plasma miR-155 were significantly up-regulated in patients with LSCC. Our work will serve as a basis for further investigation, preferably large-scale validation in clinical trials.
